宫颈HPV16/18/45型DNA检测在宫颈癌初筛阳性后分流检查中的效果评价

doi:10.3881/j.issn.1000-503X.2013.03.003

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2013, Vol. 35 ›› Issue (3): 254-259.doi: 10.3881/j.issn.1000-503X.2013.03.003

• Orignal Article • Previous Articles Next Articles

Role of HPV16/18/45 DNA Testing of Cervical Specimens as A Triage Testing in Cervical Cancer Screening

LI Jing¹,CHEN Wen¹,KANG Le-ni¹,CHEN Feng ¹,GUO Dong-ping ², LI Ba-yi²,QIAO You-lin¹

¹Department of Cancer Epidemiology,Cancer Institute & Hospital,CAMS and PUMC,Beijing 100021,China
²Medical Department,Yangcheng Women & Children’s Hospital,Yangcheng,Shanxi 048100,China

Received:2013-03-28 Online:2013-07-04 Published:2013-07-04
Contact: QIAO You-lin Tel:010-87788489,Fax:010-67713648,E-mail:qiaoy@cicams.ac.cn E-mail:qiaoy@cicams.ac.cn

Abstract

Abstract:

Objective To evaluate the clinical performance of careHPV16/18/45 DNA testing of cervical specimens as a triage testing for women with positive findings during the cervical cancer screening.Methods Eligible women aged 25-65 years were enrolled from two high-risk communities in Yangcheng County,Shanxi Province.After providing written informed consent on a voluntary base,women underwent questionnaire-based interview,gynecological examination,and sample collection.Hybrid capture 2 technology(HC2),careHPV,Avantage HPV E6 test,and visual inspection with acetic acid(VIA)were conducted as the primary screening tests at the enrollment visit.Women with any positive finding were invited to receive a second VIA and colposcopy.careHPV16/18/45 was performed as a triage testing.Any visible lesion under colposcopy was directly biopsied.Women with pathology confirmed cervical intraepithelial neoplasia grade 2 and worse(CIN2+)were treated with standard procedures.Results For the self-collected and doctor-collected samples,the application of careHPV16/18/45 as a triage testing decreased the colposcopy referral to 3.2% and 3.1%,respectively.Meanwhile,the sensitivity,specificity,and positive predictive value(PPV)for CIN2+were 50.0%,97.6%,and 26.7% for women with positive self-sampling careHPV results and 63.0%,97.9%,and 34.0% for women with positive doctor-sampling careHPV results.Conclusion careHPV16/18/45 is promising as a triage testing among women with positive screening findings in low-resource settings.

Key words: careHPV16/18/45, cervical cancer, primary screening, positive, triage

LI Jing,CHEN Wen,KANG Le-ni,CHEN Feng,GUO Dong-ping,LI Ba-yi,QIAO You-lin. Role of HPV16/18/45 DNA Testing of Cervical Specimens as A Triage Testing in Cervical Cancer Screening[J].Acta Academiae Medicinae Sinica, 2013, 35(3): 254-259.

References 18

[1]	Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J]. CA Cancer J Clin,2005,55(2):74-108.
[2]	Ronco G,Giorgi-Rossi P,Carozzi F,et al.Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia:a randomised controlled trial[J]. Lancet Oncol,2010,11(3):249-257.
[3]	Mayrand MH,Duarte-Franco E,Rodrigues I,et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer[J]. N Engl J Med,2007,357(16):1579-1588.
[4]	Bulk S,Bulkmans NW,Berkhof J,et al.Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months[J]. Int J Cancer,2007,121(2):361-367.
[5]	Naucler P,Ryd W,Tornberg S,et al.Human papillomavirus and Papanicolaou tests to screen for cervical cancer[J]. N Engl J Med,2007,357(16):1589-1597.
[6]	Sankaranarayanan R,Nene BM,Shastri SS,et al.HPV screen-ing for cervical cancer in rural India[J]. N Engl J Med,2009,360(14):1385-1394.
[7]	Bulkmans NW,Berkhof J,Rozendaal L,et al.Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer:5-year follow-up of a randomised controlled implementation trial[J]. Lancet,2007,370(9601):1764-1772.
[8]	IARC,WHO.IARC Handbooks of cancer prevention:Cervical cancer screening[M]. Lyon:IARC Press,2005.
[9]	Qiao YL,Sellors JW,Eder PS,et al.A new HPV-DNA test for cervical-cancer screening in developing regions:a cross-sectional study of clinical accuracy in rural China[J]. Lancet Oncol,2008,9(10):929-936.
[10]	Smith JS,Lindsay L,Hoots B,et al.Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions:a meta-analysis update[J]. Int J Cancer,2007,121(3):621-632.
[11]	Castle PE,Sideri M,Jeronimo J,et al.Risk assessment to guide the prevention of cervical cancer[J]. Am J Obstet Gynecol,2007,197(4):356.e1-e6.
[12]	Wright TC Jr,Massad LS,Dunton CJ,et al.2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ[J]. Am J Obstet Gynecol, 2007,197(4):340-345.
[13]	National Cancer Institute.Cervical cancer treatment(PDQ).[2013-03-06]. http://www.cancer.gov/cancertopics/pdq/treatment/cervical/HealthProfessional/page6.
[14]	Gok M,Heideman DA,van Kemenade FJ,et al.HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening:cohort study[J]. BMJ,2010,340:c1040.
[15]	Bais AG,van Kemenade FJ,Berkhof J,et al.Human papillomavirus testing on self-sampled cervicovaginal brushes:an effective alternative to protect nonresponders in cervical screening programs[J]. Int J Cancer,2007,120(7):1505-1510.
[16]	Holanda F Jr,Castelo A,Veras TM,et al.Primary screening for cervical cancer through self sampling[J]. Int J Gynaecol Obstet,2006,95(2):179-184.
[17]	Depuydt CE,Makar AP,Ruymbeke MJ,et al.BD-ProExC as adjunct molecular marker for improved detection of CIN2+after HPV primary screening[J]. Cancer Epidemiol Biomarkers Prev,2011,20(4):628-637.
[18]	Hesselink AT,Heideman DA,Steenbergen RD,et al.Combin-ed promoter methylation analysis of CADM1 and MAL:an objective triage tool for high-risk human papillomavirus DNA-positive women[J]. Clin Cancer Res,2011,17(8):2459-2465.

Acta Academiae Medicinae Sinica

Home

About Journal

Current Issue

Archive

Search

Contact Us

中文

Role of HPV16/18/45 DNA Testing of Cervical Specimens as A Triage Testing in Cervical Cancer Screening

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 18

Related Articles 15

Metrics

Recommended 10

[1]	GUO Ying,MA Dong,JIA Shifeng,LIU Jia,FAN Shaobei,ZHANG Meng,SHI Linran,JIANG Lili,SHI Juexin,WANG Haiqiu,ZHENG Huanyu,LI Ou. Proliferation of MicroRNA-365 and E74-like Factor 4 in Cervical Cancer Cells and Its Clinical Significance [J]. Acta Academiae Medicinae Sinica, 2019, 41(2): 220-227.
[2]	ZHANG Rui,ZHOU Yanli,DOU Yaling,KONG Lingjun,YE Ali,WU Jie,XU Yingchun. Infection Status of Human Papilloma Virus,Ureaplasma Urealyticum, Chlamydia Trachomatis,and Neisseria Gonorrhoeae [J]. Acta Academiae Medicinae Sinica, 2018, 40(6): 817-821.
[3]	LUO Jinmei,ZHANG Dongmei,XIAO Yi,HUANG Rong,ZHU Huijuan,YU Jianchun,ZHAO Yang. Perioperative Evaluation of Obstructive Sleep Apnea in Bariatric Surgery Population [J]. Acta Academiae Medicinae Sinica, 2018, 40(5): 617-624.
[4]	Rui ZHANG, Xinxing BI, Ali YE, Lingjun KONG, Yaling DOU. Infection Modes and Subtypes of Human Papilloma Virus in Patients [J]. Acta Academiae Medicinae Sinica, 2017, 39(4): 506-510.
[5]	Lingya CHANG, Dong MA, Ou LI, Xinyue WANG, Qi ZHANG, Lijie ZHANG, Xizhao YAN, Huanyu ZHENG. Expressions and Functions of Krüppel Like Factor 5 and Tumor Necrosis Factor Receptor Superfamily Member 11a in Cervical Cancer Tissues and Cells [J]. Acta Academiae Medicinae Sinica, 2017, 39(2): 196-205.
[6]	Qian MA, Minyi ZHAO, Xing WEI, Juan ZHAO, Ting YANG, Qian ZHANG, Kai WANG, Xiaofeng YANG. Expressions of Immune Negative Regulator FoxP3+Treg and PD-L1 Protein in the Immune Microenvironment of Cervical Lesion [J]. Acta Academiae Medicinae Sinica, 2017, 39(1): 128-132.
[7]	Min-yi ZHAO, Juan ZHAO, Ting YANG, Li WANG, Mei-li PEI, Si-juan TIAN, Yang YU, Xiao-feng YANG. Aberrant Expressions of Immune Factors Facilitate the Disequilibrium of Immune Status in Cervical Cancer [J]. Acta Academiae Medicinae Sinica, 2016, 38(5): 522-527.
[8]	Min-er ZHONG, Lai XU, Qiong XU, Wu-yang JI, Bei-zhan NIU, Hui-zhong QIU, Bin WU. Prognostic Superiority of Log Odds of Positive Lymph Nodes in Stage Ⅲ Colorectal Cancer [J]. Acta Academiae Medicinae Sinica, 2016, 38(3): 294-299.
[9]	Gu-mu-yang ZHANG, Hao SUN, Hua-dan XUE, Xiao-guang LI, Zheng-yu JIN. Computed Tomography Signs for Active Severe Gastrointestinal Bleeding [J]. Acta Academiae Medicinae Sinica, 2016, 38(3): 322-326.
[10]	Yu CHEN, Qiang FU, Wei-dong MI. Effects of Stroke Volume Variation,Pulse Pressure Variation,and Pleth Variability Index in Predicting Fluid Responsiveness during Different Positive End Expiratory Pressure in Prone Position [J]. Acta Academiae Medicinae Sinica, 2015, 37(2): 179-184.
[11]	WANG Lu,YANG Chen,ZHANG Qian,HAN Bing,ZHUANG Jun-ling,CHEN Miao,ZOU Nong,LI Jian,DUAN Ming-hui,ZHANG Wei,ZHU Tie-nan,XU Ying,WANG Shu-jie,ZHOU Dao-bin,ZHAO Yong-qiang,ZHANG Hui,WANG Peng,XU Ying-chun. Prevalence and Features of Pathogenic Bacteria in the Department of Hematology without Bone Marrow Transplantation in Peking Union Medical College Hospital from 2010 to 2012 [J]. Acta Academiae Medicinae Sinica, 2014, 36(4): 439-445.
[12]	MA Qian,HOU Meng,YANG Xiao-feng. Screening of the Genital Human Papillomavirus Infection among 8581 Women in the First Affiliated Hospital of Xi’an Jiaotong University [J]. Acta Academiae Medicinae Sinica, 2014, 36(3): 277-282.
[13]	ZHANG Jie, REN Cui, XUE Hua-dan, ZHOU Hai-long, SUN Zhao-yong, JIN Zheng-yu. Value of Diffusion-weighted Imaging in Diagnosis of Lymph Node Metastasis in Patients with Cervical Cancer [J]. Acta Academiae Medicinae Sinica, 2014, 36(1): 73-78.
[14]	LIU Qian, YANG Jia-xin, CAO Dong-yan, SHEN Keng, WU Ming, PAN Ling-ya, XIANG Yang, LANG Jing-he. Identification of Low-risk Indicators of Early Stage Cervical Cancer [J]. Acta Academiae Medicinae Sinica, 2012, 34(6): 580-584.
[15]	ZHENG Lan-rong, SHAO Jin-gui. Morphological Study on Development of Nerve Growth Factor-positiveNeurons in the Cerebellum of Human Fetus [J]. Acta Academiae Medicinae Sinica, 2012, 34(1): 46-50.